CSL Behring has shared positive four-year results from a late-stage study of its haemophilia B gene therapy Hemgenix ...

“CSL delivered a solid result for the first half of the 2025 financial year led by CSL Behring. Strong demand for many of our market-leading therapies has translated into sales growth, particularly in ...

Narrow-moat CSL reiterated fiscal 2025 guidance for constant-currency group net profit after tax before amortization, or NPATA, of USD 3.2 billion to­ USD 3.3 billion, implying 1 ...